Resource Summary Report

Generated by dkNET on Sep 6, 2026

HCC1500

RRID:CVCL_1254
Type: Cell Line

Proper Citation

RRID:CVCL_1254

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1254

Proper Citation: RRID:CVCL_1254

Description: Cell line HCC1500 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: PMID:9833771, PMID:9865903, PMID:11314036, PMID:12800145, PMID:17157791, PMID:18516279, PMID:19582160, PMID:22460905, PMID:22585861, PMID:23601657, PMID:24094812, PMID:24162158, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30787054, PMID:30894373, PMID:31068700, PMID:31395879, PMID:31978347, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1500

Synonyms: HCC-1500, Hamon Cancer Center 1500

Cross References: BTO:BTO_0006441, CLO:CLO_0003639, EFO:EFO_0001172, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2329, BioSample:SAMN03471865, BioSample:SAMN10988466, cancercelllines:CVCL_1254, Cell_Model_Passport:SIDM00879, Cosmic:687476, Cosmic:904365, Cosmic:1018471, Cosmic:1047709, Cosmic:1136374, Cosmic:1287885, Cosmic:1603203, Cosmic:1935006, Cosmic:1995424, Cosmic:2165022, Cosmic:2750522, Cosmic-CLP:1303900, DepMap:ACH-000349, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1303900, GEO:GSM217574, GEO:GSM219982, GEO:GSM344376, GEO:GSM344426, GEO:GSM350538, GEO:GSM459706, GEO:GSM783971, GEO:GSM887040, GEO:GSM888110, GEO:GSM984232, GEO:GSM1008899, GEO:GSM1053690, GEO:GSM1214571, GEO:GSM1374500, GEO:GSM1669847, IARC_TP53:22812, LiGeA:CCLE_498, LINCS_HMS:50579, LINCS_LDP:LCL-1325, PharmacoDB:HCC1500_478_2019, PRIDE:PXD030304, Progenetix:CVCL_1254, SLKBase:3524, Wikidata:Q54881583

ID: CVCL_1254

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260905T180217+0000

Ratings and Alerts

No rating or validation information has been found for HCC1500.

No alerts have been found for HCC1500.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Przanowska R, et al. (2026) IL-6R blockade with tocilizumab disrupts pericyte- and tumor cell-driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer. bioRxiv : the preprint server for biology.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell chemical biology, 33(6), 785.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. Breast cancer research : BCR, 26(1), 192.

Choi BH, et al. (2022) Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell reports, 38(3), 110278.

Aka Y, et al. (2021) Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. The international journal of biochemistry & cell biology, 137, 106028.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. Cell, 181(7), 1596.

Cotul EK, et al. (2020) Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. Cancers, 12(9).

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. Cell reports, 33(5), 108341.

Sreekumar S, et al. (2020) Differential Regulation and Targeting of Estrogen Receptor ?? Turnover in Invasive Lobular Breast Carcinoma. Endocrinology, 161(9).

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell systems, 10(1), 66.

Harris IS, et al. (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell metabolism, 29(5), 1166.

Hirukawa A, et al. (2019) Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell reports, 29(2), 249.

Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell chemical biology, 26(8), 1067.

Guan J, et al. (2019) Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell, 178(4), 949.

Wang T, et al. (2018) JAK/STAT3-Regulated Fatty Acid ??-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell metabolism, 27(1), 136.

McMillan EA, et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell, 173(4), 864.